|Bid||67.50 x 1000|
|Ask||68.50 x 100|
|Day's range||66.38 - 71.68|
|52-week range||19.08 - 74.35|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2018 - 5 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||58.79|
Biotech company Juno Therapeutics in talks to be acquired by Celgene, Newater Technology and NW Blockchain Limited to develop blockchain-based, environmental protection applications, Boeing and Adient agree to form joint venture to develop and manufacture airplane seats
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Juno Therapeutics, Inc.
The rumored acquisition of CAR-T developer Juno by Celgene has ignited investor enthusiasm for gene therapy. But in the background, concerns about how the healthcare system will afford these pricey new treatments persist.
Stocks that moved substantially or traded heavily Wednesday: Juno Therapeutics Inc., up $23.65 to $69.25 The Wall Street Journal reported that biotech drugmaker Celgene may buy the cancer therapy company. ...
Celgene could comfortably spend $11 billion to acquire Juno, an analyst said Wednesday after rumors circulated that the two biotechs could be in merger talks.
Share of Juno Therapeutics (JUNO) have surged nearly 50% on Tuesday, on rumors that it's in talks with Celgene (CELG). Reports broke late Tuesday that Celgene was considering buying Juno, which would be its second deal in as many weeks. Celgene and other big biotechs are certainly pressed to do deals to keep their growth profiles up, although the rally in the sector, especially smaller names, means that prices are high.
IBM received an upgrade as earnings from big banks and drug merger talk helped propel Wednesday's opening rally.
Among the companies with shares expected to trade actively in Wednesday's session are Goldman Sachs, Bank of America, Juno Therapeutics, Ford Motor, Alphabet and Boeing.
There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.
Juno Therapeutics surged 46% in late trading Tuesday on a report that Celgene is in talks to acquire it.
Shares of Juno, which has a market value of $5.57 billion, were up 42 percent at $64.59 in extended trading. Chimeric antigen receptor T-cell therapy, or CAR T, harnesses the body's own immune cells to recognize and attack malignant cells.
Juno Therapeutics Inc. surged after the Wall Street Journal reported that Celgene Corp. was in talks to buy the Seattle-based drugmaker.
Celgene Corp. is in talks to buy biotechnology company Juno Therapeutics Inc., just days after announcing another major deal to bolster its portfolio of blood-cancer drugs. Juno had a market value of about $5.5 billion as of Tuesday afternoon. A deal would come on the heels of Celgene’s agreement just over a week ago to buy closely held Impact Biomedicines.
Celgene Corp. is in talks to buy Juno Therapeutics Inc. , according to a report on The Wall Street Journal Tuesday that cited unnamed sources. Juno is a biotech company developing cancer treatments. Juno ...